Xlear Files Amended Answer to the Government’s Lawsuit on COVID-19 Statements; Provides Still More Data In Support of Xlear’s Use as Additional Layer of Protection
Retrieved on:
Monday, August 15, 2022
Public Policy, Government, Courts, Other Science, Research, Healthcare Reform, Science, Other Travel, Public Safety, Other Health, Travel, Pharmaceutical, Other Retail, Infectious Diseases, Other Consumer, Women, COVID-19, Seniors, Specialty, Clinical Trials, Men, Parenting, Alternative Medicine, Children, Family, Retail, Health, Consumer, Public Policy, Other Policy Issues, Vitamins, Supplements, Zinc, Death, NIH, CEO, Face, Analgesic, COVID, GSE, PMID, Pharmacology, Defendant, Research, Translation, Coronavirus, Privacy and the US government, Court, Federal government of the United States, COVID-19, Charles Degeorge, Infection, Nose, Federal Court of Canada, DOI, Federal court, Cristiane Rozeira, Decongestant, Common cold, Government, Common, Science, Severe acute respiratory syndrome coronavirus 2, Time, Disease, Pharmaceutical industry
Nate Jones, CEO of Xlear noted, The Government agrees, Xlear is a saline nasal solution.
Key Points:
- Nate Jones, CEO of Xlear noted, The Government agrees, Xlear is a saline nasal solution.
- New in silico research determined that compounds of grapefruit seed extract (GSE) were effective inhibitors of the SARS-CoV-2 virus.
- Most importantly, these experts concluded natural GSEwhich is a component of Xlearwas more effective than synthetic versions of the compound.
- As part of its efforts to silence Xlear, the Government asked the Utah Federal Court to preclude Xlear from filing the Amended Answer.